Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 31.8
(0.32%)
SEK 31.8
(0.32%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 29.64 Million SEK | -33.18% |
| 2022 | 44.36 Million SEK | 23.02% |
| 2021 | 36.06 Million SEK | 5.57% |
| 2020 | 34.16 Million SEK | 138.04% |
| 2019 | 14.35 Million SEK | 0.6% |
| 2018 | 14.26 Million SEK | 4.84% |
| 2017 | 13.6 Million SEK | -10.14% |
| 2016 | 15.14 Million SEK | 29.58% |
| 2015 | 11.68 Million SEK | 30.23% |
| 2014 | 8.97 Million SEK | 149.97% |
| 2013 | 3.59 Million SEK | -13.97% |
| 2012 | 4.17 Million SEK | 70.67% |
| 2011 | 2.44 Million SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 29.33 Million SEK | -1.04% |
| 2024 Q3 | 27.97 Million SEK | -22.52% |
| 2024 Q2 | 36.1 Million SEK | 23.06% |
| 2023 Q3 | 41.78 Million SEK | 16.92% |
| 2023 FY | 29.64 Million SEK | -33.18% |
| 2023 Q1 | 43.04 Million SEK | -2.98% |
| 2023 Q2 | 35.73 Million SEK | -16.98% |
| 2023 Q4 | 29.64 Million SEK | -29.05% |
| 2022 Q3 | 43.5 Million SEK | 14.83% |
| 2022 FY | 44.36 Million SEK | 23.02% |
| 2022 Q1 | 38.4 Million SEK | 6.49% |
| 2022 Q4 | 44.36 Million SEK | 1.99% |
| 2022 Q2 | 37.88 Million SEK | -1.36% |
| 2021 Q2 | 32.69 Million SEK | -6.33% |
| 2021 Q3 | 32.53 Million SEK | -0.48% |
| 2021 Q4 | 36.06 Million SEK | 10.84% |
| 2021 FY | 36.06 Million SEK | 5.57% |
| 2021 Q1 | 34.9 Million SEK | 2.17% |
| 2020 Q2 | 46.62 Million SEK | 13.99% |
| 2020 Q1 | 40.89 Million SEK | 184.99% |
| 2020 Q3 | 49.12 Million SEK | 5.37% |
| 2020 Q4 | 34.16 Million SEK | -30.46% |
| 2020 FY | 34.16 Million SEK | 138.04% |
| 2019 Q2 | 18.89 Million SEK | 13.86% |
| 2019 Q1 | 16.59 Million SEK | 16.35% |
| 2019 Q3 | 17.9 Million SEK | -5.24% |
| 2019 Q4 | 14.35 Million SEK | -19.86% |
| 2019 FY | 14.35 Million SEK | 0.6% |
| 2018 Q3 | 14.39 Million SEK | 7.13% |
| 2018 Q2 | 13.43 Million SEK | 12.17% |
| 2018 Q1 | 11.97 Million SEK | -11.98% |
| 2018 FY | 14.26 Million SEK | 4.84% |
| 2018 Q4 | 14.26 Million SEK | -0.89% |
| 2017 Q4 | 13.6 Million SEK | -11.27% |
| 2017 Q2 | 14.25 Million SEK | -8.03% |
| 2017 Q1 | 15.49 Million SEK | 2.33% |
| 2017 FY | 13.6 Million SEK | -10.14% |
| 2017 Q3 | 15.33 Million SEK | 7.61% |
| 2016 FY | 15.14 Million SEK | 29.58% |
| 2016 Q4 | 15.14 Million SEK | 13.34% |
| 2016 Q3 | 13.36 Million SEK | 43.12% |
| 2016 Q2 | 9.33 Million SEK | -24.67% |
| 2016 Q1 | 12.39 Million SEK | 6.05% |
| 2015 FY | 11.68 Million SEK | 30.23% |
| 2015 Q4 | 11.68 Million SEK | 4.26% |
| 2015 Q3 | 11.2 Million SEK | 7.55% |
| 2015 Q2 | 10.42 Million SEK | -12.29% |
| 2015 Q1 | 11.88 Million SEK | 32.42% |
| 2014 Q1 | 4.54 Million SEK | 26.63% |
| 2014 FY | 8.97 Million SEK | 149.97% |
| 2014 Q4 | 8.97 Million SEK | 46.25% |
| 2014 Q3 | 6.13 Million SEK | -5.95% |
| 2014 Q2 | 6.52 Million SEK | 43.51% |
| 2013 Q3 | 5.1 Million SEK | -1.41% |
| 2013 Q4 | 3.59 Million SEK | -29.73% |
| 2013 FY | 3.59 Million SEK | -13.97% |
| 2013 Q1 | 3.99 Million SEK | -4.27% |
| 2013 Q2 | 5.18 Million SEK | 29.71% |
| 2012 Q3 | 3.39 Million SEK | -8.54% |
| 2012 Q2 | 3.71 Million SEK | 0.0% |
| 2012 FY | 4.17 Million SEK | 70.67% |
| 2012 Q4 | 4.17 Million SEK | 22.95% |
| 2011 Q4 | 2.44 Million SEK | 0.0% |
| 2011 FY | 2.44 Million SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -333.484% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 75.54% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 75.54% |
| Arcoma AB | 28.02 Million SEK | -5.777% |
| BICO Group AB (publ) | 493.1 Million SEK | 93.988% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 52.49% |
| CellaVision AB (publ) | 126.03 Million SEK | 76.479% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -384.808% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -1574.044% |
| C-Rad AB (publ) | 64.09 Million SEK | 53.75% |
| Duearity AB (publ) | 4.15 Million SEK | -612.816% |
| Dignitana AB (publ) | 7.41 Million SEK | -299.919% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -701.243% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.538% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 1861.109% |
| Iconovo AB (publ) | -4.86 Million SEK | 709.749% |
| Integrum AB (publ) | 22.36 Million SEK | -32.573% |
| Luxbright AB (publ) | 8000.00 SEK | -370475.0% |
| Mentice AB (publ) | 14.1 Million SEK | -110.196% |
| OssDsign AB (publ) | 4.3 Million SEK | -588.801% |
| Paxman AB (publ) | 19.99 Million SEK | -48.237% |
| Promimic AB (publ) | 330 Thousand SEK | -8883.636% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -306.555% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -148.729% |
| ScandiDos AB (publ) | 22.69 Million SEK | -30.657% |
| Sectra AB (publ) | 36.59 Million SEK | 18.978% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 31.016% |
| Senzime AB (publ) | 20.34 Million SEK | -45.752% |
| SpectraCure AB (publ) | 1.00 SEK | -2964599900.0% |
| Stille AB | 66.55 Million SEK | 55.455% |
| Vitrolife AB (publ) | 413 Million SEK | 92.822% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 79.064% |